Experience Leucine AI.
Powered Pharma Operations

Transform Your Pharma Operations with AI-Powered Intelligence. Experience how Leucine's integrated platform brings together manufacturing, quality, and laboratory operations in one digital ecosystem. Schedule a personalized demo to see how our AI solutions can optimize your processes, ensure compliance, and drive operational excellence.

See How AI Transforms Your Shop Floor Operations.
Experience firsthand how Leucine's 10x MES digitalizes batch records, streamlines production, and provides real-time monitoring of your manufacturing operations. Schedule a personalized demo to discover how our AI-powered platform can enhance your productivity while maintaining compliance.

Experience AI-Driven Quality Management in Action.
See how Leucine's 10x QMS automates compliance workflows, streamlines change control, and ensures regulatory adherence. Schedule a demo to learn how our AI-powered platform can help you manage quality processes more efficiently while reducing compliance risks.

Discover Smart Laboratory Operations Management.
Watch how Leucine's 10x LES orchestrates your lab operations, automates documentation, and ensures data integrity. Schedule a demo to see how our AI-powered platform can accelerate your testing processes while maintaining audit-readiness.

Optimize your manufacturing processes with paperless operations
Strengthen quality management and regulatory compliance
Accelerate laboratory operations and testing workflows

Connect with a Leucine Expert

Schedule a 30-Minute Product Demo with Expert Q&A

Sub System
Alarm Management

Alarm Management

View Detailed Analysis

Analytics Overview

6
Form 483s Issued
0
483s converted to WL
7
Total Observation
Form 483s Issued
+74 from last period

Analytics Overview

Form 483 Conversion Rate by Year
Form 483s Issued (Yearly)

Recent Form 483s & Warning Letters

View all 483’s
Issue Date
Facility Name
Product Type
Form 483
Converted
Warning Letter
12 Apr 2024
Taenaka Kogyo Co., Ltd.
Drugs
04 Apr 2024
Cipla Limited
Drugs
18 Oct 2023
NATCO Pharma Limited
Drugs
21 Sep 2023
ModernaTX, Inc.
Drugs
28 Jun 2023
SterRx, LLC
Drugs

Top Investigators

Investigator Name
Form 483 Count
Warning Letter Count
Christopher R Czajka
2
0
Camerson E Moore
1
0
Edmund F Mrak
1
0
Lori M Newman
1
0
Ben Firschein, Regulatory Counsel
1
0
TITLE/ COMPANY Issue Date Status Details
Facilities for the storage of materials under controlled temperature and humidity conditions are not sufficiently monitored
Taenaka Kogyo Co., Ltd.
12 Apr 2024 Normal Justification: Observation shows that alarms are not effectively managed, risking unaddressed temperature excursions.
Excerpt: The alarm systems installed on such units throughout your facilities are configured to send email notifications to your Quality Control (QC) Manager, QC Test Manager, and Analytical Equipment Manager in the event one or more of the chambers experiences a temperature excursion.
View Details
Ventilation systems, including equipment for control of air pressure, are not adequately designed and constructed to minimize risks of contamination.
Taenaka Kogyo Co., Ltd.
12 Apr 2024 Normal Justification: Alarm systems are critical for timely alerting personnel to address pressure excursions and prevent contamination.
Excerpt: The monitoring devices used to ensure the differential pressure between the production suites and the neighboring outside environment are not equipped with alarm systems to alert personnel to pressure excursions.
View Details
The responsibilities and procedures applicable to the quality control unit are not fully followed.
Cipla Limited
04 Apr 2024 Normal Justification: Alarm Management is linked to this observation since the issues stem from the failure to follow established protocols for handling the alarms, as indicated by the lack of evidence showing required actions were taken.
Excerpt: The procedures 1035-G-0196 "Categorization and Handling of Alarms" and MT291 "Operation of (b)(4) System" are not adequately followed in case an alarm occurs for high (b) (4) (b)(4) value.
View Details
Written records are not always made of investigations into unexplained discrepancies
NATCO Pharma Limited
18 Oct 2023 Normal Justification: Equipment used in Parenteral Manufacturing Unit lacks necessary features to manage and document alarms, a crucial aspect of alarm management.
Excerpt: Major production equipment used in the sterile manufacturing of (b)(4) (b) (4) and other injectable drugs do not have the capability to store and print alarms.
View Details
Written records are not always made of investigations into unexplained discrepancies
NATCO Pharma Limited
18 Oct 2023 Normal Justification: Equipment used in Parenteral Manufacturing Unit lacks necessary features to manage and document alarms, a crucial aspect of alarm management.
Excerpt: Major production equipment used in the sterile manufacturing of (b)(4) (b) (4) and other injectable drugs do not have the capability to store and print alarms.
View Details

Prepare Better for FDA Audits with FDA Tracker

Get Real-time Insights: FDA 483s & Warning letters.
Uncover Trends: FDA Investigator profiles & Observations.
Stay Compliant: Manage risks proactively.